Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported a slight increase in total assets and net assets for the first half of 2025, despite a decline in revenue. The company saw a notable rise in net profit and operating cash flow, indicating improved operational efficiency and profitability, which could positively impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a major player in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. It holds a significant equity interest in Jiangzhong Pharmaceutical, a company listed on the Shanghai Stock Exchange, which is known for its pharmaceutical offerings in China.
Average Trading Volume: 11,891,732
Technical Sentiment Signal: Sell
Current Market Cap: HK$33.05B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.